Phase III trials aim to assess whether a new treatment has superior efficacy than a standard treatment. Sequential methods, such as the sequential probability ratio test (SPRT), the triangular test (TT) and so-called one-parameter boundaries (OPB), now allow early stopping of such trials, both in the case of efficacy (alternative hypothesis ; H 1 ) and in the case of lack of efficacy (null hypothesis ; H 0 ). We compared the statistical properties of the SPRT and the TT, and of OPB with Pocock (OPB ∆ = 0.5 ) and O'Brien and Fleming (OPB ∆ = 0 ) type boundaries, in the setting of one-sided comparative trials with normal response. We studied the type I error (α), power (1kβ), average sample number (ASN) and 90th percentile (P90) of the number of patients required to reach a conclusion using simulations. The four tests were also compared with the corresponding single-stage design (SSD). All sequential tests display α and 1kβ close to nominal values and, as compared with SSD, allow important decreases in ASN : for example, k48 %, k42 %, k40 % and k31 % under H 0 and H 1 for SPRT, TT, OPB ∆ = 0.5 and OPB ∆ = 0 respectively. For situations between H 0 and H 1 , ASNs of all sequential tests were still smaller than the sample size required by SSD, with the TT displaying the largest decrease (k25 %). The P90s of the TT and OPB ∆ = 0 under H 0 and H 1 were smaller than the P90s of the SPRT and OPB ∆ = 0.5 , which were similar to the sample size required by SSD. If all sequential tests display approximately similar features, the TT is the most appealing regarding decreases in sample size, especially for situations between H 0 and H 1 .
INTRODUCTION
Clinical trial design depends on the purpose of the trial, which itself depends on the phase of drug development. For instance, phase III trials aim to assess whether a new treatment has superior efficacy than a standard treatment. Thus these trials are usually comparative ones. In practice, the reference approach is the single-stage design (SSD), and the statistical test is performed after the inclusion and evaluation of a predetermined sample size.
This sample size is computed at the planning phase in order to detect, in a test performed at the α level, a difference of clinical interest (reference improvement) between the two treatments with a power 1kβ. However, the SSD can be difficult to implement because of ethical problems (impossibility of stopping an ongoing trial even if the early data show a clear difference between treatments) and\or economic reasons (the sample size being sometimes very large). Thus specific early termination procedures have been developed [1] [2] [3] [4] [5] . These procedures, the so-called sequential methods, allow repeated statistical analyses to be performed throughout the trial recruitment period in order to allow the trial to be stopped as soon as the information accumulated is considered sufficient to reach a conclusion. The need for such procedures results directly from the fact that performing repeated analyses on accumulating data can substantially increase the probability of wrongly declaring a difference between treatments (type I error ; α) [6] . Thus all the sequential methods that have been developed allow for early termination of a trial while maintaining a pre-specified α level.
Two main procedures can be identified. The first derives from a ' boundaries ' approach and includes the sequential probability ratio test (SPRT) and the triangular test (TT), extended by Whitehead [5] from the initial works of Wald [7] and Anderson [8] . The second derives from a ' repeated significance testing ' approach, and includes group sequential methods such as those of Pocock [1] , O'Brien and Fleming [2] , Lan and DeMets [3] and Wang and Tsiatis [4] . The repeated significance testing approach consists of performing several conventional analyses using adjusted significance levels to allow for repeated testing [6] . In this setting, a nominal significance level αh α, which can be the same for all analyses [1] or different from one analysis to the other [2] , is used to maintain some predetermined overall significance level α. A classic test statistic is computed at each analysis and its value is compared with a critical value corresponding to the adjusted significance level. Pocock [1] and O'Brien and Fleming [2] were among the first workers to develop group sequential methodology by modifying the initial work of Armitage [9] . Lan and DeMets [3] generalized their work with the α-spending function, which allows the characterization of the rate at which the α error is spent. It is a continuous increasing function of the so-called information fraction (information observed at a given time divided by the total information expected at the scheduled termination of the study) chosen at the planning phase. Its specification determines a boundary of critical values and, as special cases, allows approximation of the Pocock [1] and O'Brien and Fleming [2] boundaries. Moreover, this type of analysis does not require equally spaced analyses. Wang and Tsiatis [4] also generalized the work of Pocock [1] and O'Brien and Fleming [2] by focusing on the expression of the boundaries. They proposed a class of boundaries indexed by a single parameter, the so-called one-parameter boundaries (which we shall refer to as OPB), which includes, as special cases, Pocock and O'Brien and Fleming boundaries. These OPB are based on equally spaced analyses, but they have been found to behave well in the case of departures from this assumption. These two methods, which allowed early stopping of trials only in the case of treatment efficacy, were developed further to also allow early stopping in the case of lack of efficacy [10, 11] . Pampallona and Tsiatis [10] developed a β-spending function, similar to the α-spending function, allowing characterization of the rate at which the β error is spent, and Emerson and Fleming [11] used the OPB in the context of symmetric group sequential test designs (with α l β).
The latest versions of all these procedures, namely the SPRT, TT, spending functions and OPB, display features that are quite appealing. They allow early stopping of trials, not only in the case of clear efficacy but also in the case of complete lack of efficacy. Furthermore, they allow great flexibility during the monitoring of clinical trials, since they do not require the number of subjects to be the same in successive analyses, and neither do they require the number of subjects to be the same in the two treatment groups at each analysis. Moreover, all these methods allow comparison of two distributions with different endpoints (qualitative, quantitative, censored variables), and two types of software (PEST [12] and EaSt [13] ) are available for the planning, monitoring and analysis of clinical trials, which makes their use quite simple. However, whether all of these sequential methods in their latest versions can be considered equivalent with regard to statistical properties remains unknown. The purpose of our work was therefore to study the statistical properties of the SPRT, TT and OPB with Pocock and O'Brien and Fleming type boundaries by simulations of the type I error rate, power, average sample number (ASN) and 90th percentile (P90) of the number of patients required in order to reach a conclusion, and to compare all these methods between themselves and with the SSD.
METHODS
Phase III trials aim to assess whether a new treatment has superior efficacy than a standard treatment. In statistical terms, the problem amounts to comparing two observed distributions. If θ represents a measure of the difference between these two distributions, the problem can be expressed as the test of the null hypothesis H 
SPRT and TT
The SPRT and the TT use a sequential plan defined by two perpendicular axes [5] . The horizontal axis corresponds to a first statistic, V, which represents the quantity of information accumulated since the beginning of the trial (Fisher's information for the parameter of interest). The vertical axis corresponds to a second statistic, Z, which represents the benefit as compared with the null hypothesis (efficiency score for the parameter of interest). Two straight lines, called the boundaries of the test, delineate a continuation region (situated in between these lines) from the region of non-rejection of the null hypothesis (situated beneath the bottom line) to the region of rejection of the null hypothesis (situated above the top line). In the SPRT, these boundaries are parallel, so that the continuation region is open, whereas in the TT they are convergent, thus defining a closed continuation region with a triangular shape (Figure 1 ). The equations of these boundaries are given in Appendix 1. Both statistics Z and V are computed under the null hypothesis. They are calculated after each group of patients has been evaluated. In the case of a comparative trial with a quantitative endpoint, the test statistics Z and V are given by :
in which n i is the cumulative number of patients (since the beginning of the trial) in group i (i l 1, 2). xa i is given by
where x ij denotes the observed response of patient j in group i. D is the maximum likelihood estimate of σ under the null hypothesis :
At each analysis, Z is plotted against V. The trial is continued as long as the sample path remains in the continuation region. A conclusion is reached as soon as the sample path crosses one of the boundaries of the test. The null hypothesis is rejected if the sample path crosses the upper boundary ; it is not rejected if the lower boundary is crossed.
The OPB approach
We used the boundaries given by the software EaSt [13] , in which spending functions (α and β) and OPB are combined. This approach consists of comparing a statistic, which is calculated after each group of patients has been evaluated, to a boundary value which depends on α, β, θ R , the boundary shape parameter ∆ (i.e. the parameter which determines the boundary type), and the maximum number of analyses to be performed, K. The choice of ∆ l 0.5 yields the Pocock boundary, and ∆ l 0 yields the O'Brien and Fleming boundary. We shall refer to these boundaries as OPB ∆ = !.& and OPB ∆ = ! respectively. The description of the principles of the spending functions for the type I error α and type II error β are given in Appendix 2.
We expressed the whole procedure in terms of the same statistics, Z and V, as were used for the SPRT and the TT (Figure 2 ). The procedure is as follows : the statistics Z and V are computed at each analysis as described previously, and the value of Z\NV is compared with those of the boundaries (see Appendix 3). The null hypothesis is rejected if the upper boundary is crossed, it is not rejected if the lower boundary is crossed, and the trial is continued if neither boundary is crossed. As with the TT, the boundaries of the OPB meet, thus avoiding very long trial duration. 
Simulation design
We studied the properties of the SPRT, the TT, OPB ∆ =!.& and OPB ∆ = ! by computer simulations. The type I error α and power 1kβ, the ASN and P90 were evaluated for all tests. A total of 30 000 comparative trials were generated in which patient responses were drawn from a normal distribution with mean µ " equal to 10 and standard deviation σ equal to 5. We investigated the influence of various values of β and θ R on the statistical properties of all tests. The influence of the total number of patients evaluated at each analysis (n), which was taken to be the same for all successive analyses, on the statistical properties of the SPRT and the TT was evaluated. We also evaluated the influence of the maximum number of analyses to be performed, K, on the statistical properties of OPB ∆ = !.& and OPB ∆ = ! (in this case, the number of patients evaluated at each analysis was the maximum number of patients given by EaSt divided by K). Namely we chose two different values for β (0.05 and 0.10), seven values for θ R (0.4, 0.5, 0.6, 0.7, 0.8, 0.9 and 1.0), five values for n (4, 8, 12, 16 and 20) and five values for K (3, 4, 5, 6 and 7). The value of α was set to 0.05 for all simulated trials. For the SSD, the number of patients was calculated in order to ensure that significance at the α level was found with a probability 1kβ if θ l θ R . A total of 30 000 comparative trials were generated, and the fixed-sample analysis was conducted by using the one-sided t-test. Tables 1 and 2 show the type I error and power for different values of θ R and β for the SSD, SPRT (n l 12), TT (n l 12), OPB ∆ =!.& (K l 5) and OPB ∆ = ! (K l 5). As expected, the significance level was close to the target value of 0.05 for the SSD for all values of θ R and β. The significance level achieved by the SPRT and the TT was quite accurate for almost all values of θ R and β, but increased slightly for the SPRT as θ R increased. For instance, when θ R l 0.9 and β l 0.05, the significance level was 0.066 for the SPRT, whereas it was 0.054 for the More precisely, the TT performed better than OPB ∆ = !.& for θ R 0.7, whereas the two tests were equivalent for θ R 0.7. When θ l θ R \2, the ASNs of all sequential tests were always smaller than the number of patients required by the SSD, whatever values of θ R and β were considered. The TT displayed the largest decrease in sample size, followed by the SPRT, OPB ∆ = !.& and OPB ∆ = ! , which were very similar to one another. Indeed, as compared with the SSD, an approx. 25 % decrease in sample size was observed for the TT, and an approx. Table 2 Power for the SSD, the SPRT and the TT, and for OPB ∆ = 0.5 and OPB ∆ = 0 , for different values of the expected benefit θ R and β (α l 0.05) . The P90 values of the sample size distribution of all sequential tests when θ l θ R \2 were higher than the required sample size for the SSD. The highest value of P90 was obtained for the SPRT. Indeed, as compared with the SSD, a 65 % increase was observed for the SPRT, Table 3 ASN required to reach a conclusion under H 0 /H 1 and when θ l θ R /2 for the SPRT, the TT, OPB ∆ = 0.5 and OPB ∆ = 0 , and sample size for the SSD, for different values of the expected benefit θ R and β (α l 0.05) 
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DISCUSSION
We studied the statistical properties of the SPRT, the TT and of the OPB with Pocock and O'Brien and Fleming type boundaries by simulation, with regard to the type I error α, the power 1kβ, the ASN and the P90 of the number of patients required to reach a conclusion. We applied all tests to comparative trials in which the response was assumed to be normally distributed. The Table 5 Influence of the frequency of the analyses on the type I error, power, ASN and P90 of the number of patients required to reach a conclusion under H 0 /H 1 and when θ l θ R /2 for the SPRT and the TT when θ R l 0.7 (α l 0.05) ' Christmas tree ' correction [5, 14] and the spending function approach [3] were used to adjust for the discrete monitoring of the data. Simulation studies showed that all sequential tests allow smaller ASNs as compared with the SSD, while maintaining the desired significance level and power. Indeed, with regard to the ASN under H suggested [22] , increasing the number of analyses seems to be quite interesting when using the new versions allowing also for early acceptance of H ! . From a methodological viewpoint, some characteristics of our study are worth a mention. Firstly, we have only considered the case of normal responses, which is not too restrictive, since most tests of hypotheses, which are computed after groups of observed data, are approximately normally distributed. Secondly, patients were analysed as batches of size n when simulating the SPRT and TT, while they were analysed as K equally sized batches when simulating OPB ∆ = !.& and OPB ∆ = !
SPRT TT
. Computational convenience led us to choose such a simulation scenario, and all tests could in fact easily be evaluated under any of these scenarios (either batches of size n or K equally sized batches). Thirdly, we expressed the whole procedure using the OPB in terms of the same statistics, Z and V, as were used for the SPRT and TT ; these statistics could also be used in this setting because the α-spending function approach is connected to the theory of Brownian motion process, and the sample path of Z against V can also be approximated by Brownian motion [5] (see Appendix 3) .
Several approaches to the sequential monitoring of multiple endpoints have also been proposed. They mostly address the problem of multivariate normal measurements [23] [24] [25] [26] , but multiple survival outcomes [27, 28] have also been studied. All these approaches allow the use of sequential methods in the design and analysis of trials in which the primary clinical concern is the trade-off between the chance of improved efficacy and toxicity (as encountered in trials of aggressive treatments for fatal disease). Even though sequential methods are used more and more in various therapeutic areas [29] [30] [31] [32] [33] , selection of the proper statistical design (whether SSD or sequential) always depends on the type of clinical study about to be conducted, and there are many clinical trials for which the SSD remains most appropriate (for instance, trials in which the endpoint is obtained very slowly compared with the recruitment rate).
Bayesian methods offer another approach to the sequential analysis of clinical trials [34, 35] . Such methods come from the Bayes theorem, which formalizes the notion of having prior belief (clinician's opinion) which is then modified according to the observed data, yielding revised posterior belief. Such methods have been used in some clinical trials [36] , but their application remains somewhat controversial due to the difficulty in choosing a suitable prior distribution that provides an estimate of the potential therapeutic benefit.
Finally, it is worth mentioning that all these methods are only part of the numerous criteria that are used by independent Data Monitoring Committees to decide whether a clinical trial should be stopped early or not. Indeed, many other types of information should also be taken into account, such as recruitment celerity, the occurrence of serious adverse events, publication of results answering the question raised by the trial, etc. In some cases, the statistical stopping rules can even be overwhelmed by other considerations, such as new recommendations that interfere with the trial [37] .
In conclusion, of the sequential tests, the TT seems to be the most appealing with regard to statistical properties : type I and II errors are correctly maintained to their desired values, and it offers a substantial decrease in sample size compared not only with the SSD but also with most of the other tests, whatever the frequency of the analyses. As compared with the SPRT, the TT is to be preferred, since the latter uses a closed sequential design. Moreover, in many clinical trials the truth, that is the ' true ' value of the parameter of interest, often lies between the two hypotheses H ! and H " , and the TT is more efficient than all the other tests with regard to the amount of information required in such a case.
APPENDIX 1 Stopping boundaries for the SPRT and the TT
The lower and upper stopping boundaries with working significance level α are the following : Z lkajbV and Z l ajbV for the SPRT, and Z lkaj3cV and Z l ajcV for the TT. a l ahk0.583NI for both tests ; ah l (1\θ R ):log [(1kα)\α], b l " # θ R for the SPRT, and ah l (2\θ R ):logn(1\2α), c l " % θ R for the TT ; I l V i kV i−" for the SPRT and the TT. V i is the information which is available at inspection i, and V ! is taken to be equal to 0. These boundaries are computed for continuous monitoring of the data and guarantee a power of 1kα (β l α). In the case of discrete monitoring of the data, these boundaries must be corrected (' Christmas tree ') [1, 2] . When β α, a corrected value of θ R , θh R , must be used to compute the equations of the boundaries, which can be obtained by the approximate formula :
where Φ denotes the standard normal distribution function. The value θh R can be detected by the test with power 1kα.
